



Media Release

Singapore's Tripartite Alliance for Fair and Progressive Employment Practices Recognises Cordlife as a Human Capital Partner

SINGAPORE, 30 April 2018 – Singapore mainboard-listed Cordlife Group Limited (“**Cordlife**” or the “**Company**”) announced today it has been officially recognised as a Human Capital Partner (“**HCPartner**”) under the Human Capital Partnership Programme (“**HCP Programme**”), for its efforts towards developing human capital as well as the adoption of fair and progressive workplace practices. As a HCPartner, Cordlife will have better access to government support and resources, and can expect quicker responses from relevant state agencies for manpower matters.

Set up in 2007 by the Ministry of Manpower, the Tripartite Alliance for Fair and Progressive Employment Practices (“**TAFEP**”) promotes the adoption of fair, responsible and merit-based employment practices among employers, employees and the general public. The HCP Programme is a tripartite initiative by TAFEP, to develop a community of employers committed to training and nurturing their Singapore workers.

Companies under the HCP Programme must invest in Singaporean employees of all ages and levels; ensure proper transfer of expertise from foreign staff to locals to fill skill gaps; and select foreigners who complement local workers. Through this recognition, Cordlife joins the ranks of over 130 HCPartners which include Capitaland Group, Mediacorp and DBS Bank.

Since 2009, Cordlife has been investing in human capital which includes developing its internal high potential talents through external training programmes as well as hiring of young talents from local polytechnics and universities. The Company has also implemented good welfare practices such as regular reviews of employee medical benefits and providing flexible work arrangement.

“We aspire to be an exemplary employer as our most important asset is really our people. When they are equipped and empowered to do their job, the entire organisation succeeds. This is why we invest a lot of time and resources to developing our human capital.” said Ms Tan Poh Lan, Group COO of Cordlife. She received the HCP certificate from the Second Minister for Manpower, Mrs Josephine Teo at the Conference on Fair and Progressive Employment Practices 2018 on 27 April 2018.

End



Media & Investor Contact Information

WeR1 Consultants Pte Ltd

3 Phillip Street, #12-01, Royal Group Building

Singapore 048693

Tel: (65) 6737 4944

Frankie Ho – frankieho@wer1.net

Grace Yew – graceyew@wer1.net

About Cordlife Group Limited

(Bloomberg: CLGL; Reuters: CORD.SI)

Incorporated in 2001, Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”) is a consumer healthcare company and one of the leading providers of cord blood as well as cord lining banking services in Asia. Cordlife has been listed on the mainboard of Singapore Exchange (SGX: P8A) since March 2012.

Cordlife owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six key markets, namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singapore, the Philippines and Indonesia, Cordlife operates the largest private cord blood banks; and is amongst the top three market leaders in India and Malaysia. In January 2018, Cordlife became the market leader in Hong Kong with the acquisition of the largest private cord blood bank in the country, HealthBaby Biotech (Hong Kong) Co., Limited. Through its majority owned subsidiary, Stemlife Berhad in Malaysia, Cordlife controls an indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. Cordlife is also the first Singapore private cord blood bank to provide cord blood and cord lining banking services in Myanmar and Vietnam.

Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services for the mother and child segment including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and other genetic screening services.

The Group's stem cell processing and storage facilities in Singapore, Hong Kong, India and the Philippines are accredited by AABB, the organisation behind the world's gold standard for cord blood banking. Cordlife Singapore is also accredited by FACT-Netcord, another world-class accreditation body for cord blood banks globally. This makes Cordlife Singapore one of just six private cord blood banks in the world to be accredited by both AABB and FACT-Netcord simultaneously.

The Group's majority-owned Hong Kong Screening Centre and Cordlife India also attained accreditation from the College of American Pathologists (“CAP”) for meeting the highest industry standards for laboratory services. These quality achievements underpin the Group’s commitment to providing the highest service quality for clients. For more information, visit <http://cordlife.listedcompany.com>.